drugset
Drugs / BS01
last change Jan 2026 re-read 3 minutes ago

BS01

also known as AAV2-CAGChronosFP

Gene therapy (AAV / viral vector)

Developed for
dry age related macular degeneration · retinitis pigmentosa
Investigated by
Bionic Sight LLC

Trials 2

today NCT07158775 · Ph 1/2 NCT04278131 · Ph 1/2
202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT07158775 Jan 2026 → Dec 2027 expected dry age related macular degeneration Bionic Sight LLC Recruiting No outcome recorded
Phase 1/2 NCT04278131 Feb 2020 → Dec 2026 expected retinitis pigmentosa Bionic Sight LLC Recruiting No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as BS01 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07158775 ↗
1

NCT04278131 ↗
Known as AAV2-CAGChronosFP “A Phase 1/2, Safety and Efficacy Trial of BS01, a Recombinant Adeno-Associated Virus Vector Expressing ChronosFP (AAV2-CAG-ChronosFP) in Patients with Retinitis Pigmentosa” NCT04278131 ↗
1

“BS01, a recombinant adeno-associated virus vector expressing ChronosFP (AAV2-CAGChronosFP)” NCT07158775 ↗
Modality Gene therapy (AAV / viral vector) “a Recombinant Adeno-Associated Virus Vector” NCT04278131 ↗
Route Intravitreal “Intravitreal Administration” NCT07158775 ↗